CD69 and neoplasm: Eight newly collected fresh tumor samples following immunochemotherapy (from 5 patients later assessed as MPR and 3 patients later assessed as NR, based on standardized pathology reports reviewed by multiple pathologists) and 3 samples following chemotherapy were used to evaluate PD-1 expression in CD3+CD4+CD69+CCR7+CD127+ cells.